InvestSMART

EMvision Medical Devices Limited (ASX:EMV)

ALERT: Price-sensitive ASX Announcement for EMV
Current share price for EMV : $1.570 -0.28 (-15.14%)+
Announcement
Release
27 Nov 2025 8:23AM
Price at Release
$1.850
Full Release
download
Summary
EMVision Medical Devices Limited has launched a pivotal aeromedical feasibility and usability study for its innovative First Responder Brain Scanner in partnership with the Royal Flying Doctor Service, the Australian Stroke Alliance, and the South Australian Ambulance Service. This study is critical to evaluating the device's operational feasibility and usability in pre-hospital and remote aeromedical settings, primarily focusing on the rapid and accurate diagnosis of stroke, a significant unmet need in rural regions. The study will offer invaluable data to refine the device's design and operational workflow, ensuring it is ready for commercial and regulatory approval. With an expected completion in the first quarter of 2026, the study aims to empower healthcare teams to make prompt, evidence-based decisions to enhance stroke patient outcomes, particularly in remote areas where timely neuroimaging is a challenge.
Key Points
  • EMVision Medical Devices Limited has commenced an aeromedical feasibility and usability study for its First Responder device.
  • The study is conducted in collaboration with the Royal Flying Doctor Service, Australian Stroke Alliance, and South Australian Ambulance Service.
  • The study aims to evaluate the operational feasibility and usability of the EMVision First Responder Brain Scanner in pre-hospital aeromedical environments.
  • The study has significant implications for early and accurate diagnosis of acute stroke in remote and rural settings.
  • The study will refine commercial product design, training materials and support clinical and regulatory activities.
  • EMVision seeks to improve care accessibility and equality in stroke patient outcomes through its portable, cost-effective brain scanning device.
  • The study is expected to complete in the first quarter of 2026.
  • The study includes objectives to assess usability, integration into workflows, and environmental robustness.
  • The study is essential for de-risking the real-world deployment of the device and informing the final commercial device design.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.